General Information
Vaccine: Moderna COVID-19 Vaccine
Multidose vial*: 
Primary series doses only: maximum of 11 doses
Booster doses only: maximum of 20 doses
Combination of primary series and booster doses: maximum of 20 doses
Do NOT puncture the vial stopper more than 20 times
Dosage:
- Primary series and additional primary dose: 0.5 mL
- Booster dose: 0.25 mL

Age Indications
18 years of age and older

Vaccination Schedule
For an up-to-date vaccination schedule for primary, additional (for moderately or severely immunocompromised persons), and booster doses of Moderna COVID-19 Vaccine, see https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-5yrs-older.pdf

Administration
Intramuscular (IM) injection in the deltoid muscle

Thawing Frozen Vaccine
- Frozen vaccine must be thawed before using.

Prepare and Administer the Vaccine
Assess recipient status:
- Screen for contraindications and precautions.
- Review vaccination history.
- Review medical considerations.

Follow aseptic technique. Perform hand hygiene before vaccine preparation, between patients, when changing gloves (if worn), and any time hands become soiled.†

Vaccine must be thawed before using. If removing the vial from the refrigerator, let it stand at room temperature for 15 minutes.

Unpunctured vials: Check the expiration date. Never use expired vaccine.

Punctured vials: Check the beyond-use time and ensure the vial stopper has not been punctured more than 20 times. Never use vaccine past the beyond-use date or puncture limit.

With the vial upright, gently swirl the vaccine. Do NOT shake. If the vial is shaken, contact the manufacturer. Note: Gently swirl the vaccine before withdrawing subsequent doses.

Examine the vaccine. It should be white to off-white in color and may contain white or translucent particles. Do not use if liquid contains other particulate matter or is discolored.

Using a new, sterile alcohol prep pad, cleanse the stopper of the multidose vaccine vial.

Choose the correct equipment, including the correct needle size. Use a new, sterile needle and syringe for each injection.

Ensure the needle and syringe are secured tightly together to prevent the vaccine from inadvertently leaking during preparation and administration.

* There are 2 presentations of Moderna COVID-19 Vaccine authorized by FDA. Currently only Moderna COVID-19 Vaccine with a red cap and a light blue border on the label is available to order. Additional guidance will be forthcoming.

† Gloves are not required unless the person administering the vaccine is likely to come in contact with potentially infectious body fluids or has open lesions on the hands. If worn, perform hand hygiene and change gloves between patients.
Prepare and Administer the Vaccine (continued)

Withdraw the correct dosage of vaccine into the syringe (0.5 mL for primary and additional primary doses; 0.25 mL for booster dose).*

Ensure the prepared syringe is not cold to the touch.
- Discard vial when there is not enough vaccine to obtain a complete dose.
- Do NOT combine residual vaccine from multiple vials to obtain a dose.
- Regardless of the type of syringe used, ensure the amount of vaccine in the syringe is correct.

Once you can no longer withdraw a complete dose from a vaccine vial, dispose of the vial (with any remaining vaccine) as medical waste according to your local and state regulations. Contact your jurisdiction’s immunization program (https://www.cdc.gov/vaccines/imz-managers/awardee-imz-websites.html) for guidance.

Bring the dose of vaccine from the designated preparation area immediately to the patient treatment area for administration.

Ensure staff has the correct PPE before administering vaccine and implement policies for the use of face coverings for vaccine recipients (if tolerated).

Administer the vaccine immediately by intramuscular (IM) injection in the deltoid muscle.

Observe recipients after vaccination for an immediate adverse reaction:
- **30 minutes:** Persons with a history of:
  - A contraindication to another type of COVID-19 vaccine product
  - Immediate (within 4 hours of exposure) non-severe allergic reaction to a COVID-19 vaccine
  - Immediate allergic reaction of any severity to a non-COVID-19 vaccine or injectable therapies
  - Anaphylaxis due to any cause
- **15 minutes:** All other persons

Note the date and time the vial was first punctured. Keep the vaccine between 2°C and 25°C (36°F and 77°F) for up to 12 hours. Do NOT puncture vial stopper more than 20 times. Discard any unused vaccine after 12 hours.

Contraindications and Precautions

**Contraindications:**

History of a:
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine
- Known diagnosed allergy to a component of the vaccine (see https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#Appendix-C for a list of vaccine components)

**Precautions:**

- History of immediate allergic reaction† to any non-COVID-19 vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies [excluding subcutaneous immunotherapy for allergies, i.e., “allergy shots”])
- History of a non-severe, immediate allergic reaction‡ after a dose of COVID-19 vaccine
- Allergy-related contraindication to one type of COVID-19 vaccines (mRNA) is a precaution to other types of COVID-19 vaccines (Janssen)§
- History of multisystem inflammatory syndrome in children (MIS-C) and adults (MIS-A)
- History of myocarditis or pericarditis after a dose of an mRNA COVID-19 vaccine
- Moderate to severe acute illness, with or without fever

For more information, please see Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States at www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html.

* It is not necessary to change needles between drawing vaccine from a vial and injecting it into a recipient unless the needle has been damaged or contaminated

† An immediate allergic reaction is defined as any hypersensitivity-related signs or symptoms such as urticaria, angioedema, respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occur within 4 hours following exposure to a vaccine or medication.

‡ Consider consultation with an allergist-immunologist to help determine if the patient can safely receive vaccination. Healthcare providers and health departments may also request a consultation from the Clinical Immunization Safety Assessment COVIdVax Project https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html. Vaccination of these individuals should only be done in an appropriate setting under the supervision of a healthcare provider experienced in the management of severe allergic reactions.

§ People with a contraindication to mRNA COVID-19 vaccines (including due to a known PEG allergy) have a precaution to Janssen COVID-19 vaccination. People who have previously received an mRNA COVID-19 vaccine dose should wait at least 28 days to receive Janssen COVID-19 Vaccine.

‡ An immediate allergic reaction is defined as any hypersensitivity-related signs or symptoms such as urticaria, angioedema, respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occur within 4 hours following exposure to a vaccine or medication.

Consider consultation with an allergist-immunologist to help determine if the patient can safely receive vaccination. Healthcare providers and health departments may also request a consultation from the Clinical Immunization Safety Assessment COVIdVax Project https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html. Vaccination of these individuals should only be done in an appropriate setting under the supervision of a healthcare provider experienced in the management of severe allergic reactions.

- People with a contraindication to mRNA COVID-19 vaccines (including due to a known PEG allergy) have a precaution to Janssen COVID-19 vaccination. People who have previously received an mRNA COVID-19 vaccine dose should wait at least 28 days to receive Janssen COVID-19 Vaccine.
- People with a contraindication to Janssen COVID-19 Vaccine (including due to a known polysorbate allergy) have a precaution to mRNA COVID-19 vaccination.
Management of Anaphylaxis

Be prepared to manage medical emergencies.

- Have a written protocol to manage medical emergencies following vaccination, as well as equipment and medications, including at least 3 doses of epinephrine, H1 antihistamine, blood pressure monitor, and timing device to assess pulse.

- Healthcare personnel who are trained and qualified to recognize the signs and symptoms of anaphylaxis as well as administer intramuscular epinephrine should be available at the vaccination location at all times.


Document the Vaccination

COVID-19 vaccination providers must document vaccine administration in their medical record systems within 24 hours of administration and use their best efforts to report administration data to the relevant system (i.e., immunization information system) for the jurisdiction as soon as practicable and no later than 72 hours after administration.

Document each recipient's vaccine administration information in the:

- **Medical record**
  - Vaccine and the date it was administered
  - Manufacturer and lot number
  - Vaccination site and route
  - Name and title of the person administering the vaccine

- **Personal vaccination record card (shot card):**
  - Date of vaccination
  - Product name/manufacturer
  - Lot number
  - Name/location of the administering clinic or healthcare professional
  - Give to the vaccine recipient.

- **Immunization information system (IIS) or “registry”:**
  - Report the vaccination to the appropriate state/local IIS.

Reporting Adverse Events

Healthcare professionals are required to report to the Vaccine Adverse Event Reporting System (VAERS):

- Vaccine administration errors (whether associated with an adverse event [AE] or not)
- Serious AEs (irrespective of attribution to vaccination)
- Multisystem inflammatory syndrome (MIS) in adults or children
- Cases of COVID-19 that result in hospitalization or death
- Any additional AEs and revised safety reporting requirements per the Food and Drug Administration’s conditions for use of an authorized vaccine throughout the duration of the EUA

Adverse events should be reported even if the cause is uncertain. Healthcare professionals are also encouraged to report any clinically significant AEs that occur after vaccine administration. Submit reports to [www.vaers.hhs.gov](http://www.vaers.hhs.gov).

For additional information, see the vaccine manufacturer’s product information at [www.modernatx.com/covid19vaccine-eua/](http://www.modernatx.com/covid19vaccine-eua/).

For additional information on preventing, reporting, and managing mRNA COVID-19 vaccine administration errors, see [www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html#Appendix-A](http://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html#Appendix-A).